Invention Grant
- Patent Title: Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen
-
Application No.: US16088386Application Date: 2016-11-22
-
Publication No.: US11324819B2Publication Date: 2022-05-10
- Inventor: Edward Clark , Deborah L. Fuller , Che-Leung Law , Amanda Mak
- Applicant: UNIVERSITY OF WASHINGTON
- Applicant Address: US WA Seattle
- Assignee: UNIVERSITY OF WASHINGTON
- Current Assignee: UNIVERSITY OF WASHINGTON
- Current Assignee Address: US WA Seattle
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- International Application: PCT/US2016/063246 WO 20161122
- International Announcement: WO2017/176319 WO 20171012
- Main IPC: A61K39/00
- IPC: A61K39/00 ; A61K39/29 ; A61K39/39 ; C07K16/28 ; C12N7/00
Abstract:
Provided herein are compositions of CD1280 binding proteins and a Hepatitis B virus core antigen (HBcAg) and/or a Hepatitis B virus E antigen (HBeAg), or antigenic fragments or mutants thereof, attached to the CD180 binding protein, and methods for using the compositions to treat or limit the development of hepatitis-B virus (HBV)-related disorders.
Public/Granted literature
- US20200306367A1 Therapeutic Vaccine for Hepatitis B Virus (HBV) using the HBV Core Antigen Public/Granted day:2020-10-01
Information query
